Search Result

Results for "

myeloproliferative

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (17) Bcr-Abl (2) c-Myc (1) Deubiquitinase (1) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (2) Epigenetic Reader Domain (3) Fatty Acid Synthase (FASN) (1) FGFR (2) FLT3 (2) Glutathione Peroxidase (1) HDAC (1) Interleukin Related (1) Isotope-Labeled Compounds (2) JAK (22) LDLR (1) Ligands for Target Protein for PROTAC (1) MARK (1) Microtubule/Tubulin (1) PARP (1) PDGFR (1) PDK-1 (1) Phosphodiesterase (PDE) (2) PROTACs (2) Reactive Oxygen Species (ROS) (1) Reference Standards (3) RET (1) ROS Kinase (1) SOD (1) STAT (9) Stearoyl-CoA Desaturase (SCD) (1) Telomerase (1) TNF Receptor (1) Wee1 (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (6) Infection (1) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (1)
Oligonucleotides:	Antisense Oligonucleotides (1)

Inhibitors & Agonists

Bibliotecas de Screening

Biochemical Assay Reagents

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-10409

Fedratinib Maximum Cited Publications 51 Publications Verification TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-10409A

Fedratinib hydrochloride hydrate Maximum Cited Publications 51 Publications Verification TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-124727

ZT55	JAK Apoptosis	Cancer
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC₅₀ value of 0.031 μM. ZT55 inhibits the proliferation of JAK2 ^V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia .

HY-B0523

Anagrelide 3 Publications Verification	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-12854

Imetelstat GRN163L	Telomerase Apoptosis	Cardiovascular Disease Cancer
Imetelstat (GRN163L) is a 13-mer oligonucleotide and competitive Telomerase inhibitor. Imetelstat binds with high affinity to the template region of the RNA component of human telomerase. Imetelstat induces Apoptosis. Imetelstat is capable of selectively eliminating myelofibrosis hematopoietic stem cells. Imetelstat leads to the loss of a cancer cell's ability to maintain telomere length, resulting in the inhibition of cell proliferation .

HY-P99348

Ropeginterferon alfa-2b Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b	Apoptosis	Cancer
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .

HY-146186

JAK2 JH2 binder-1	JAK	Cancer
JAK2 JH2 binder-1 (compound 11) is a potent and selective JAK2 JH2 binder, with a K_d of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research .

HY-16398

Pipobroman	DNA Alkylator/Crosslinker DNA/RNA Synthesis	Cancer
Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al .

HY-164393

ON044580	JAK Bcr-Abl Apoptosis	Cancer
ON044580, an α-benzoyl styryl benzyl sulfide, is a potent and non-ATP-competitive JAK2 kinase inhibitor with IC₅₀s of 1.23 μM, 1.09 μM for WT and V617F mutant JAK2, respectively. ON044580 inhibits the JAK2 kinase activity either by binding to the STAT-5 binding domain of JAK2 or by binding to an allosteric site. ON044580 exerts its antiproliferative effect in JAK2 ^V617F-positive leukemic cells. ON044580 effectively induces apoptosis of Imatinib (HY-15463)-resistant chronic myelogenous leukemia (CML) cells. ON044580 also inhibits both WT and T315I mutant forms of the BCR-ABL kinase. ON044580 has the potential for myeloproliferative disorders typified by aberrant JAK/STAT signaling .

HY-161684

JAK2-IN-10	JAK STAT	Cancer
JAK2-IN-10 is a selective JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM . JAK2-IN-10 can be used for the research of myeloproliferative neoplasms and other related diseases .

HY-175684

JAK2-IN-14	JAK STAT Apoptosis	Cancer
JAK2-IN-14 is an orally active JAK2 inhibitor with an IC₅₀ of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over JAK1, JAK3, and TYK2, respectively. JAK2-IN-14 inhibits STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs) .

HY-W070306

PDK1-IN-1	PDK-1 FGFR Wee1 MARK	Neurological Disease Cancer
PDK1-IN-1 (Compound 2-11) is a PDK1 inhibitor. PDK1-IN-1 is also useful as inhibitor of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. PDK1-IN-1 selectively inhibits microtubule affinity regulating kinase (MARK). PDK1-IN-1 can be used for researches of myeloproliferative disorders, cancer and Alzheimer's disease .

HY-174428

PROTAC JAK2 degrader-1	PROTACs JAK STAT Apoptosis	Cancer
PROTAC JAK2 degrader-1 is a JAK2 PROTAC degrader, with a DC₅₀ of 27.35 nM. PROTAC JAK2 degrader-1 induces JAK2 degradation via the ubiquitin-proteasome pathway. PROTAC JAK2 degrader-1 inhibits the JAK2-STAT signaling pathway. PROTAC JAK2 degrader-1 induces G₂/M phase arrest and apoptosis in cancer cells. PROTAC JAK2 degrader-1 exhibits antiproliferative activity against cancer cells. PROTAC JAK2 degrader-1 inhibits recombinant human erythropoietin (rhEPO)-mediated polycythemia and splenomegaly in mice. PROTAC JAK2 degrader-1 can be used for research on myeloproliferative neoplasms, including polycythemia vera .

HY-16020

AC-430 hydrobromide	JAK	Cancer
AC-430 hydrobromide (example 1) is a potent JAK2 inhibitor. AC-430 hydrobromide can be used for the research of myeloproliferative disorders and cancer .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective JAK2 inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-10409R

Fedratinib (Standard) TG-101348 (Standard); SAR 302503 (Standard)	Reference Standards JAK Apoptosis	Cancer
Fedratinib (Standard) is the analytical standard of Fedratinib. This product is intended for research and analytical applications. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-176274

FASN/SCD-IN-1	Fatty Acid Synthase (FASN) Stearoyl-CoA Desaturase (SCD) Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor SOD LDLR Glutathione Peroxidase	Metabolic Disease Inflammation/Immunology
FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH .

HY-174988

JAK2-IN-13	JAK STAT	Cancer
JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC₅₀ of 54.7 nM. JAK2-IN-13 downregulates the expressions of p-STAT3 and p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms .

HY-16398R

Pipobroman (Standard)	DNA Alkylator/Crosslinker DNA/RNA Synthesis Reference Standards	Cancer
Pipobroman (Standard) is the analytical standard of Pipobroman. This product is intended for research and analytical applications. Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al .

HY-10409AR

Fedratinib hydrochloride hydrate (Standard) TG-101348 hydrochloride hydrate (Standard); SAR 302503 hydrochloride hydrate (Standard)	Reference Standards JAK Apoptosis	Cancer
Fedratinib (hydrochloride hydrate) (Standard) is the analytical standard of Fedratinib (hydrochloride hydrate). This product is intended for research and analytical applications. Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-118084

LS-104 Tyrene CR-4	JAK Bcr-Abl FLT3 Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against JAK2, Bcr-Abl and FLT3. LS-104 potently induces apoptosis in JAK2V617F-positive cells and inhibits JAK2 autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies .

HY-123289

CP-690550A	JAK	Inflammation/Immunology
CP-690550A is an analogue of Tofacitinib (HY-40354). CP-690550A is a dual inhibitor of JAK2 and JAK3 .

HY-10409S

Fedratinib-d9 TG-101348-d₉; SAR 302503-d₉	Isotope-Labeled Compounds Apoptosis JAK	Cancer
Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-B0523S

Anagrelide-13C2,15N,d2	Apoptosis Phosphodiesterase (PDE) Isotope-Labeled Compounds	Cardiovascular Disease Cancer
Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-186043

Menin-MLL-IN-35	Epigenetic Reader Domain	Metabolic Disease Cancer
Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC₅₀ value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes .

HY-186044

Menin-MLL-IN-36	Epigenetic Reader Domain	Metabolic Disease Cancer
Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC₅₀ value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes .

HY-136734

JAK2-IN-5	JAK	Inflammation/Immunology
JAK2-IN-5 (Compound 13) is a selective JAK kinase inhibitor, with an IC₅₀ of 0.078 μM against JAK-2 and an IC₅₀ of 0.206 μM against JAK-2 ^V617F. JAK2-IN-5 can be used for the research of myeloproliferative disorders .

HY-174430

WWQ-131	Ligands for Target Protein for PROTAC JAK	Cancer
WWQ-131 is a potent selective JAK2 inhibitor with an IC₅₀ of 2.56 nM. WWQ-131 shows >252-fold selectivity over JAK1, JAK3, and TYK2. WWQ-131 exhibits antiproliferative activity against cancer cells. WWQ-131 is the ligand for target protein for PROTAC JAK2 degrader-1 (HY-174428). WWQ-131 can be used for the research of myeloproliferative neoplasms (MPNs) .

HY-182720

FT108	HDAC Microtubule/Tubulin	Cancer
FT108 is a selective HDAC6 inhibitor with an IC₅₀ of 0.026 μM. FT108 exhibits only modest in vitro activity against HDAC3 and HDAC8 with IC₅₀ values of 6.68 and 4.07 μM. FT108 increases acetylation of tubulin and has little to no effect on acetylated histone H3 levels. FT108 lacks activity against myeloproliferative neoplasm cell lines, and does not suppress JAK2 phosphorylation or its downstream targets pSTAT3 and pSTAT5 .

HY-P991888

INCA033989	STAT	Cardiovascular Disease Cancer
INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (K_D = 1.75 nM for mutCALR ^del52; K_D = 6.78 nM for mutCALR ^ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .

HY-180177

PROTAC BLIMP-1 degrader-1	PROTACs	Cancer
PROTAC BLIMP-1 degrader-1 (Compound 49) is a PROTAC-based BLIMP-1 degrader. PROTAC BLIMP-1 degrader-1 promotes the ubiquitination and degradation of BLIMP-1 and can be used in research on myeloproliferative tumors .

HY-179687

JAK2-IN-18	JAK STAT	Cardiovascular Disease
JAK2-IN-18 (Compound example1) is a selective JAK2 inhibitor. JAK2-IN-18 can inhibit JAK-STAT signaling and shows an IC₅₀ of <100 nM for pSTAT5 in HEL9217 cells. JAK2-IN-18 can inhibit the proliferation of abnormally proliferating myeloid cells and can be used for the research of myeloproliferative disorders, such as essential thrombocythemia .

HY-180561

WWQ-03-012	Deubiquitinase JAK STAT Apoptosis	Cancer
WWQ-03-012 is a selective deSUMOylating isopeptidases DESI2 inhibitor with an IC₅₀ of 47.3 μM. WWQ-03-012 cans induce JAK2-V617F ubiquitination-proteasome degradation with no significant effect on wild-type JAK2. WWQ-03-012 can block JAK2-STAT3/5 signaling, inhibit cell proliferation and induce apoptosis. WWQ-03-012 has a synergistic effect in combination with Ruxolitinib (HY-50856), further enhancing its killing effect on JAK2 mutant cells. WWQ-03-012 can be used for the research of cancer, such as myeloproliferative neoplasms .

HY-182430

NVP-BVB808	JAK STAT Apoptosis	Cancer
NVP-BVB808 is a selective and ATP-competitive JAK2 inhibitor with an IC₅₀ of 0.35 nM. NVP-BVB808 binds to JAK2’s ATP-binding site, stabilizes JAK2’s active conformation, increases JAK2 activation loop phosphorylation, and blocks downstream kinase function. NVP-BVB808 exhibits antiproliferative and pro-apoptosis effects, suppresses constitutive STAT5a phosphorylation. NVP-BVB808 can be used for the research of cancer, such as leukemia .

HY-115541

BRD4-IN-41	Epigenetic Reader Domain JAK FLT3 RET ROS Kinase PDGFR FGFR c-Myc STAT Apoptosis PARP	Cancer
BRD4-IN-41 is a BRD4 inhibitor with an IC₅₀ of 34 nM. BRD4-IN-41 also inhibits JAK2, FLT3, RET, ROS1, NTRK3, PDGFRb, and FGFR1 kinases with IC₅₀ values ranging from 0.9 nM to 43 nM. BRD4-IN-41 inhibits acetyl-lysine binding site of BRD4, downregulates c-MYC, reduces phosphorylated STAT3 levels, induces G1 cell cycle arrest and apoptosis, thereby inhibiting cancer cells growth. BRD4-IN-41 can be used for the research of cancer, such as multiple myeloma and acute myeloid leukemia .

Cat. No.	Nombre del producto

HY-L171

Anti-Hematopathy Compound Library	4,172 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 4,172 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

4,172 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 4,172 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

PDK1-IN-1	Biochemical Assay Reagents
PDK1-IN-1 (Compound 2-11) is a PDK1 inhibitor. PDK1-IN-1 is also useful as inhibitor of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. PDK1-IN-1 selectively inhibits microtubule affinity regulating kinase (MARK). PDK1-IN-1 can be used for researches of myeloproliferative disorders, cancer and Alzheimer's disease .

Cat. No.	Nombre del producto	Target	Research Area	Image

HY-P99348

Ropeginterferon alfa-2b Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b	Apoptosis	Cancer
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .

HY-P991888

INCA033989	STAT	Cardiovascular Disease Cancer
INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (K_D = 1.75 nM for mutCALR ^del52; K_D = 6.78 nM for mutCALR ^ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .

Species:	Human (4) Mouse (2)
Tag:	His (5) Tag Free (1)
Source:	HEK293 (5) E. coli (1)

Cat. No.	Compare	Nombre del producto	Species	Source	Image

HY-P704528

	TPO/Thrombopoietin Protein, Human (HEK293) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Human	HEK293
	TPO/Thrombopoietin Protein, a lineage-specific cytokine, significantly influences megakaryocyte proliferation and maturation, particularly in late developmental stages from committed progenitor cells. It emerges as a potential major physiological regulator, underscoring its crucial role in the intricate orchestration of circulating platelets and emphasizing its importance in megakaryocyte biology and platelet formation. TPO/Thrombopoietin Protein, Human (HEK293) is the recombinant human-derived TPO/Thrombopoietin protein, expressed by HEK293, with tag free.

HY-P700155AF

	Animal-Free TPO/Thrombopoietin Protein, Human (His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Human	E. coli
	TPO/Thrombopoietin Protein, a lineage-specific cytokine, significantly influences megakaryocyte proliferation and maturation, particularly in late developmental stages from committed progenitor cells. It emerges as a potential major physiological regulator, underscoring its crucial role in the intricate orchestration of circulating platelets and emphasizing its importance in megakaryocyte biology and platelet formation. Animal-Free TPO/Thrombopoietin Protein, Human (His) is the recombinant human-derived animal-FreeTPO/Thrombopoietin protein, expressed by E. coli , with N-His labeled tag. This product is for cell culture use only.

HY-P70686

	TPO/Thrombopoietin Protein, Mouse (HEK293, N-His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Mouse	HEK293
	TPO/Thrombopoietin Protein, a lineage-specific cytokine, crucially regulates megakaryocyte proliferation and maturation, acting in the late stages of development from committed progenitor cells. Recognized as a major physiological regulator, TPO significantly influences circulating platelets, emphasizing its importance in the intricate process of platelet formation. TPO/Thrombopoietin Protein, Mouse (HEK293, N-His) is the recombinant mouse-derived TPO/Thrombopoietin protein, expressed by HEK293 , with N-6*His labeled tag.

HY-P70637A

	TPO/Thrombopoietin Protein, Human (HEK293, C-His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Human	HEK293
	TPO/Thrombopoietin Protein, Human (HEK 293, His) is a recombinant protein produced in HEK293 cells with a His tag. TPO is a growth factor for the megakaryocytic/platelet lineage.

HY-P70686A

	TPO/Thrombopoietin Protein, Mouse (HEK293, C-His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Mouse	HEK293
	TPO/Thrombopoietin Protein, a lineage-specific cytokine, crucially regulates megakaryocyte proliferation and maturation, acting in the late stages of development from committed progenitor cells. Recognized as a major physiological regulator, TPO significantly influences circulating platelets, emphasizing its importance in the intricate process of platelet formation. TPO/Thrombopoietin Protein, Mouse (HEK293, C-His) is the recombinant mouse-derived TPO/Thrombopoietin protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70637

	TPO/Thrombopoietin Protein, Human (HEK293, C/N-His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; myeloproliferative leukemia virus oncogene ligand; THPO	Human	HEK293
	TPO/Thrombopoietin Protein, Human (HEK 293, His) is a recombinant protein produced in HEK293 cells with a His tag. TPO is a growth factor for the megakaryocytic/platelet lineage.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Añadir al carrito Obtener un presupuesto

Cat. No.	Nombre del producto	Chemical Structure

HY-161684

JAK2-IN-10
JAK2-IN-10 is a selective JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM . JAK2-IN-10 can be used for the research of myeloproliferative neoplasms and other related diseases .

HY-10409S

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-B0523S

Anagrelide-13C2,15N,d2

Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

Host:	Rabbit (2)
Reactivity:	Human (2) Rat (2) Mouse (2)
Application:	WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1) Recombinant (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Nombre del producto	Application	Reactivity	Image

HY-P82496

	Thrombopoietin Receptor Antibody (YA2241) MPL; TPOR; Thrombopoietin receptor; TPO-R; myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD110	WB	Human, Mouse, Rat
	Thrombopoietin Receptor Antibody (YA2241) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Thrombopoietin Receptor.

HY-P82496A

	Thrombopoietin Receptor Antibody (YA2241)(PBS only) MPL; TPOR; Thrombopoietin receptor; TPO-R; myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD110	WB	Human, Mouse, Rat
	Thrombopoietin Receptor Antibody (YA2241) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Thrombopoietin Receptor.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Añadir al carrito Obtener un presupuesto

Cat. No.	Nombre del producto		Classification

HY-12854

Imetelstat GRN163L		Antisense Oligonucleotides
Imetelstat (GRN163L) is a 13-mer oligonucleotide and competitive Telomerase inhibitor. Imetelstat binds with high affinity to the template region of the RNA component of human telomerase. Imetelstat induces Apoptosis. Imetelstat is capable of selectively eliminating myelofibrosis hematopoietic stem cells. Imetelstat leads to the loss of a cancer cell's ability to maintain telomere length, resulting in the inhibition of cell proliferation .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: